In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Background: A limited number of approved therapeutic options are available to metastatic medullary thyroid cancer (MTC) patients, and the response to conventional chemotherapy and/or radiotherapy strategies is inadequate. Sporadic and inherited mutations in the tyrosine kinase RET result in oncogeni...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bentzien, Frauke, Zuzow, Marcus, Heald, Nathan, Gibson, Anna, Shi, Yongchang, Goon, Leanne, Yu, Peiwen, Engst, Stefan, Zhang, Wentao, Huang, Donghui, Zhao, Lora, Vysotskaia, Valentina, Chu, Felix, Bautista, Rajana, Cancilla, Belinda, Lamb, Peter, Joly, Alison H., Yakes, F. Michael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Mary Ann Liebert, Inc. 2013
Gaiak:
Thyroid Cancer and Nodules
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868259/
https://ncbi.nlm.nih.gov/pubmed/23705946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2013.0137
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak